Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (6 of 6) Show all publications
Asif, S., Tu, H.-F., White, R. A., Birgisdottir, B., Lipcsey, M., Bjurström, M. F. & Skalkidou, A. (2026). Labour epidural analgesia and early childhood behavioural outcomes: the moderating role of maternal mental health and pro-inflammatory cytokines. Anaesthesia
Open this publication in new window or tab >>Labour epidural analgesia and early childhood behavioural outcomes: the moderating role of maternal mental health and pro-inflammatory cytokines
Show others...
2026 (English)In: Anaesthesia, ISSN 0003-2409, E-ISSN 1365-2044Article in journal (Refereed) Epub ahead of print
Abstract [en]

INTRODUCTION: Labour epidural analgesia is the most effective method for intrapartum pain relief and is associated with improved maternal outcomes. However, concerns have been raised regarding potential associations between labour epidural analgesia and adverse psycho-emotional outcomes in children. Evidence from large epidemiological studies is inconsistent and potential biological mechanisms remain unclear. Maternal immune activation during pregnancy may play a role. We aimed to investigate behavioural and psycho-emotional outcomes in children of mothers who received epidural analgesia during labour, accounting for perinatal mental health, sociodemographic characteristics and cytokine profiles.

METHODS: Singleton vaginal births from the Biology, Affect, Stress, Imaging and Cognition study were included. Child behavioural outcomes were assessed by Child Behavioural Checklist scores at 18 months, 6 years and 11 years postpartum in the U-BIRTH follow-up cohort, with higher scores indicating more behavioural difficulties. The main exposure was maternal use of labour epidural analgesia. Maternal data were collected from questionnaires and medical records.

RESULTS: Among 1962 mother-child dyads, 726 (37%) received labour epidural analgesia. Younger maternal age; lower resilience; inflammatory diseases; primiparity; antenatal depression; fear of childbirth; and longer duration of labour were associated with higher Child Behavioural Checklist scores at 18 months postpartum. In crude analysis, labour epidural analgesia correlated with higher Child Behavioural Checklist scores at 18 months postpartum; however, this association was not significant after adjusting for confounders. Among those with lower expression of TNFSF14 and CXCL6 cytokines, labour epidural analgesia use was associated with higher Child Behavioural Checklist scores.

DISCUSSION: Use of epidural analgesia during labour was not found to be independently associated with adverse child behavioural outcomes. Variations in maternal cytokine profiles among those choosing labour epidural analgesia or not may influence susceptibility to early behavioural differences. Replication in larger cohorts and further exploration of additional immune biomarker dynamics during pregnancy are warranted.

Place, publisher, year, edition, pages
John Wiley & Sons, 2026
Keywords
CBCL scores, labour epidural analgesia, late gestation cytokines, postpartum depression, resilience
National Category
Anesthesiology and Intensive Care Gynaecology, Obstetrics and Reproductive Medicine
Identifiers
urn:nbn:se:uu:diva-583128 (URN)10.1111/anae.70203 (DOI)001722527500001 ()41833518 (PubMedID)2-s2.0-105032895205 (Scopus ID)
Available from: 2026-03-25 Created: 2026-03-25 Last updated: 2026-03-30Bibliographically approved
Clark, K. D., White, R. A., Jackson, S. S., Skalkidou, A., Frisell, T. & Papadopoulos, F. C. (2026). Nationwide estimates of all-cause and cause-specific mortality among individuals with gender dysphoria in Sweden, 2001-2023: a register-based cohort study. eClinicalMedicine, 98, Article ID 104088.
Open this publication in new window or tab >>Nationwide estimates of all-cause and cause-specific mortality among individuals with gender dysphoria in Sweden, 2001-2023: a register-based cohort study
Show others...
2026 (English)In: eClinicalMedicine, E-ISSN 2589-5370, Vol. 98, article id 104088Article in journal (Refereed) Published
Abstract [en]

Background

Transgender and gender-diverse (TGD) people experience elevated mortality risk, yet population-based estimates of cause-specific mortality remain limited. Prior studies have focused on narrow subgroups or outdated cohorts, leaving gaps in understanding current mortality disparities. Therefore, the purpose of this study is to quantify all-cause and cause-specific mortality among all TGD adults with a diagnosis of gender dysphoria in Sweden.

Methods

This cohort study provides national cause-specific mortality estimates among TGD adults in Sweden using registry data (2001–2023). TGD people were identified using ICD-10 codes for “gender dysphoria” and matched to approximately 10 cisgender controls of each sex by age and county. Age-standardized mortality rates, absolute mortality risk differences, mortality rate ratios (MRR), and years of potential life lost (YPLL) were calculated overall and stratified by sex assigned at birth.

Findings

A total of 9038 TGD people were identified, among them, 211 deaths were observed. All-cause mortality risk was almost twice that of the cisgender comparison group (MRR = 1.9, 95% confidence interval [CI] 1.7, 2.2). Stratified analyses showed distinct mortality patterns for transfeminine (assigned male sex at birth) and transmasculine (assigned female sex at birth) people, with higher risk from ill-defined diseases among transfeminine people (cisgender women as reference: MRR = 4.9, 95% CI 2.3, 10.3; cisgender men: MRR = 5.5, 95% CI 2.6, 11.4) and transmasculine people from neoplasms (cisgender women: MRR = 2.4, 95% CI 1.4, 4.1; cisgender men: MRR = 1.8, 95% CI 1.1, 3.1). These disparities resulted in a mean of 6.3 YPLL for transfeminine people compared to cisgender men and 9.0 YPLL for transmasculine people compared to cisgender women.

Interpretation

These findings highlight persistent health inequities and underscore the need for targeted public health interventions and an evaluation of data collection processes to improve health monitoring and support TGD populations in Sweden.

Place, publisher, year, edition, pages
Elsevier, 2026
Keywords
Transgender, Gender dysphoria, Mortality, Register-based study, Health disparities, Cohort study
National Category
Public Health, Global Health and Social Medicine
Identifiers
urn:nbn:se:uu:diva-595808 (URN)10.1016/j.eclinm.2026.104088 (DOI)001839816500001 ()42576911 (PubMedID)2-s2.0-105046099652 (Scopus ID)
Funder
Forte, Swedish Research Council for Health, Working Life and Welfare, 2023-01397Forte, Swedish Research Council for Health, Working Life and Welfare, 2021-01968
Available from: 2026-08-19 Created: 2026-08-19 Last updated: 2026-08-19Bibliographically approved
Buer, S., Hagen, B. I., Søraas, A., White, R., Lerdal, A., Nygaard, A. B. & Stubberud, J. (2026). Subjective and objective working memory deficits in the post-acute phase of COVID-19 in a clinical trial population. Brain, Behavior, and Immunity - Health, 55, Article ID 101278.
Open this publication in new window or tab >>Subjective and objective working memory deficits in the post-acute phase of COVID-19 in a clinical trial population
Show others...
2026 (English)In: Brain, Behavior, and Immunity - Health, E-ISSN 2666-3546, Vol. 55, article id 101278Article in journal (Refereed) Published
Abstract [en]

Importance

Cognitive difficulties are commonly reported following COVID-19, yet the relationship between subjective and objective working memory (WM) deficits remains unclear. Examining both types of measures may improve understanding of cognitive complaints in individuals with persistent post-COVID-19 symptoms.

Objective

This cross-sectional study aimed to describe WM deficits in a clinical trial population with self-reported persistent cognitive difficulties >6 months following COVID-19, compare the frequency of scores exceeding clinical cutoffs on subjective versus objective measures, and explore how these frequencies vary according to demographic, clinical, and selected COVID-19-related characteristics.

Methods

We used baseline data from a preregistered randomized controlled trial (Hagen et al., 2022). Participants (N = 129) with perceived executive function deficits aged 26-65 years, and at least one prior laboratory-confirmed SARS-CoV-2 infection were included. Subjective WM was assessed using the Behavior Rating Inventory of Executive Function-Adult Version, Working memory subscale. Objective WM was measured using Digit Span from the Wechsler Adult Intelligence Scale and Spatial Working Memory from Cambridge Neuropsychological Test Automated Battery. Participants also completed questionnaires on anxiety and depression, fatigue, and insomnia.

Results

Participants more frequently exceeded the clinical threshold (T >= 65) for subjective WM deficits than for objective WM deficits (1.5 SD below normative mean). Higher levels of anxiety and depression were associated with a higher frequency of exceeding clinical thresholds for subjective, but not objective, WM deficits. Conclusion: In this selected clinical trial population of individuals with persistent self-reported cognitive difficulties following COVID-19, subjective WM deficits were more frequent than objective WM deficits. The findings reveal a low association between subjective and objective WM deficits in the post-acute phase of COVID-19 recovery and indicate that non-cognitive factors, particularly anxiety and depression symptoms, may be relevant when evaluating subjective WM complaints following COVID-19.

Place, publisher, year, edition, pages
Elsevier, 2026
Keywords
Neuropsychology, Executive functioning, Working memory deficits, Post-COVID-19 condition, Cognitive functioning, Neuropsychological assessment
National Category
Neurosciences Geriatrics
Identifiers
urn:nbn:se:uu:diva-593806 (URN)10.1016/j.bbih.2026.101278 (DOI)001797253300001 ()42317295 (PubMedID)2-s2.0-105040988577 (Scopus ID)
Available from: 2026-07-08 Created: 2026-07-08 Last updated: 2026-07-08Bibliographically approved
Clark, K. D., White, R. A., Karamanis, G., Indremo, M., Özel, F., Skalkidou, A., . . . Papadopoulos, F. (2025). Stability After Legal Gender Change Among Adults With Gender Dysphoria. JAMA Network Open, 8(9), Article ID e2527780.
Open this publication in new window or tab >>Stability After Legal Gender Change Among Adults With Gender Dysphoria
Show others...
2025 (English)In: JAMA Network Open, E-ISSN 2574-3805, Vol. 8, no 9, article id e2527780Article in journal (Refereed) Published
Abstract [en]

ImportanceThe number of people seeking treatment for gender dysphoria (GD) has risen in recent decades, yet data remain limited for understanding cases of detransition (ie, the reversal of social, medical, or legal transition). Legal gender change in national registers poses an opportunity to examine legal gender reversals, which may reflect an aspect of the detransition process, while also informing an understanding of the stability after a legal gender change. ObjectiveTo determine the probability of obtaining a legal gender change and its stability over time among people diagnosed with GD in Sweden during a 10-year study period. Design, Setting, and ParticipantsIn this population cohort study using data from Swedish national registers from January 1, 2013, to December 31, 2023, individuals who received their first International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10), diagnosis code for GD during the study period were included. While participants may have received a GD ICD-10 code as youths, legal gender changes only occurred for adults (aged >= 18 years) based on legal requirements during the time of data collection. ExposureGender dysphoria. Main Outcomes and MeasuresLegal gender change and its stability, that is, absence of legal gender reversal, as reported in the registry. Kaplan-Meier survival analysis was used to determine the probability of legal gender change and its stability during a 10-year study period. ResultsA total of 7293 people with a GD diagnosis were included (36 025 person-years). Approximately one-third of the sample (n = 2467) obtained a legal gender change during the study period. The probability of legal gender change at 10 years following diagnosis was 58.3% (95% CI, 56.2%-60.4%). Twenty-one cases of legal gender reversal were identified. The probability of legal gender stability at 10 years following the initial change was 97.7% (95% CI, 96.3%-99.2%), with no differences by sex assigned at birth for either outcome. Conclusions and RelevanceIn this cohort study using national population registry data, a significant proportion of participants with GD in Sweden obtained legal gender change within 10 years of follow-up. Despite significant growth of the population with GD, the probability of legal gender stability during the 10-year study period was high, at almost 98%. These results highlight that legal gender reversal was an infrequent occurrence in a national sample.

Place, publisher, year, edition, pages
American Medical Association (AMA), 2025
National Category
Psychiatry
Identifiers
urn:nbn:se:uu:diva-568248 (URN)10.1001/jamanetworkopen.2025.27780 (DOI)001566859200002 ()40906480 (PubMedID)
Funder
Forte, Swedish Research Council for Health, Working Life and Welfare, 2023-01397
Available from: 2025-10-08 Created: 2025-10-08 Last updated: 2025-10-08Bibliographically approved
Gidén, K., Duque Björvang, R., White, R. A., Vinnerljung, L., Iliadis, S., Skalkidou, A. & Fransson, E. (2024). Remission or Persistence?: A Prediction Tool to Identify Women at Risk for Long-Term Depressive Symptoms Postpartum. Depression and anxiety (Print), 2024, Article ID 7734542.
Open this publication in new window or tab >>Remission or Persistence?: A Prediction Tool to Identify Women at Risk for Long-Term Depressive Symptoms Postpartum
Show others...
2024 (English)In: Depression and anxiety (Print), ISSN 1091-4269, E-ISSN 1520-6394, Vol. 2024, article id 7734542Article in journal (Refereed) Published
Abstract [en]

Background. Peripartum depression is a common complication with potential long-term adverse effects on the woman and her family. Approximately 30%-50% of newly delivered women experience prolonged depressive symptoms at 6-12 months postpartum. Early detection may facilitate preventive and treatment interventions. Aim. To investigate correlates for and create a tool for predicting long-term symptomatology in women experiencing depressive symptoms at 6 weeks postpartum.

Materials and Methods. Data from the Biology, Affect, Stress, Imaging, and Cognition study was used, to identify women who scored high (>= 12) on the Edinburgh Postnatal Depression Scale (EPDS) at 6 weeks postpartum (n = 697). Further, we collected data from medical records and included 40 variables based on earlier studies and clinical experience. A total of 654 women were included. Elastic net linear regression analysis was performed to identify predictors of continued symptoms at 6 months postpartum. An equation predicting the EPDS score at 6 months postpartum based on weighted variables was developed.

Results. High education level and sleep for more than 6 hr per night in pregnancy week 17 were protective factors. Parity, pregnancy complications, stressful events, attention deficit hyperactivity disorder/attention deficit disorder, history of depression, depressive symptoms, and anxiety during pregnancy were predictive factors of prolonged depressive symptoms. A prediction tool with area under curve 0.73 and positive predictive value of 79%-83% depending on chosen EPDS cutoff was developed for clinical use.

Conclusions. Our prediction tool offers a method to identify women at risk for persisting depressive symptoms postnatally, based on their significant depressive symptoms during the first weeks after delivery. Screening in order to identify these women can already start in the antenatal setting.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024
National Category
Gynaecology, Obstetrics and Reproductive Medicine Psychiatry
Identifiers
urn:nbn:se:uu:diva-538835 (URN)10.1155/2024/7734542 (DOI)001307178800001 ()
Funder
Swedish Research Council, 2023-01928Swedish Research Council, 523-2014-2342Swedish Research Council, 523-2014-07605Marianne and Marcus Wallenberg Foundation, MMW2011.0115Swedish Society of Medicine, SLS-250581
Available from: 2024-09-20 Created: 2024-09-20 Last updated: 2026-03-05Bibliographically approved
Indremo, M., Engberg, A., White, R. A., Frisell, T., Isaksson, J., Skalkidou, A. & Papadopoulos, F.Exploring the impact of autism on treatment outcomes following gender-affirming hormonal treatment and top-surgery.
Open this publication in new window or tab >>Exploring the impact of autism on treatment outcomes following gender-affirming hormonal treatment and top-surgery
Show others...
(English)Manuscript (preprint) (Other academic)
Abstract [en]

 Background: Studies comparing outcomes following gender-affirming care between autistic and non-autistic individuals with gender dysphoria (GD) are scarce.Objective: To assess whether gender-affirming hormone therapy (GAHT) and top surgery reduce symptoms of gender incongruence (GI) and GD and enhance body satisfaction, and to examine if these associations are influenced by autistic traits or autism diagnosis.Design: Multicenter longitudinal cohort study within a target trial emulation framework (TTE).Setting: The Swedish Gender Dysphoria Study recruited 514 participants from six specialized gender identity clinics in Sweden between 2016 and 2022, with up to a three-year longitudinal follow-up.Participants:  A subset of 120 participants who received GAHT were compared to 246 participants who had not yet initiated treatment. Additionally, 65 participants who underwent top surgery following GAHT were compared to 134 participants who received GAHT only.Exposure: Data on GAHT and top surgeries were obtained from the National Prescribed Drugs Register, the National Patient Register and supplemented by self-reported survey data.Main outcomes and measures: GI, GD, and body satisfaction were assessed using the Transgender Congruence Scale, Gender Congruence and Life Satisfaction Scale, and Body Image Scale, supplemented by Visual Analogue Scale ratings at baseline and  up to three years post-treatment. We used linear mixed models (LMMs) within a Bayesian estimation framework, with time modeled as a natural cubic spline, retaining all longitudinal outcome data to account for within-person variation.Results: In the GAHT cohort, 67 (56%) among the treated were assigned female at birth, and 59 (49%) exhibited autistic traits. Among those undergoing top surgery, 57 (88%) were assigned female at birth, and 34 (52%) had autistic traits. Posterior estimates from the LMM supported the hypothesis that GAHT yields credible reductions in GI up to 31 months post-treatment, with delayed but credible improvements in GD and body satisfaction, though with increasing uncertainty over time. Top surgery was associated with sustained reductions in GI and early credible improvements in GD and body satisfaction, although posterior uncertainty increased in later follow-up periods. No significant interactions were found between GAHT or top surgery and autistic traits or autism diagnosis for any of the outcomes.Conclusion and relevance: GAHT is associated with improvements in core outcomes, particularly regarding GI, with further benefits following top surgery. No evidence was found to indicate that autistic traits or an autism diagnosis significantly moderate these associations. These results do not support the need for separate guidelines for access to gender-affirming interventions based solely on ASD status.

Keywords
Gender dysphoria, autism, gender-affirmation
National Category
Medical and Health Sciences
Research subject
Medical Science
Identifiers
urn:nbn:se:uu:diva-554975 (URN)
Available from: 2025-04-20 Created: 2025-04-20 Last updated: 2025-04-21
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-6747-1726

Search in DiVA

Show all publications